These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date 2004-004710-16 An open label, multicenter, randomized, phase 3 study of S-1 in combination with cisplatin compared against 5-FU in combination with cisplatin in patients with advanced gastric cancer previously untre... 2017-04-03 bad-data
Not reported 2005-003272-38 AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, TWO-STAGE, PHASE 2 STUDY OF S-1 IN CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER. 2008-07-08 due-trials
Listed as ongoing, but also has a completion date 2007-007629-32 A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, INTERNATIONAL, MULTICENTER STUDY OF ORAL TAC 101 AS SECOND LINE TREATMENT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA WHO RECEIVED SORAF... 2010-05-07 bad-data
Listed as ongoing, but also has a completion date 2009-016019-39 An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin compared with 5-FU and Cisplatin in patients with metastatic diffuse gastric cancer previously untreated with chemiotherapy 2017-01-19 bad-data
Listed as ongoing, but also has a completion date and reported results 2012-000109-66 RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAS-102 PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN PATIENTS WITH METASTATIC COLORECTAL CANCER REFRACTORY TO STANDARD CHEMOTHERAPIES 2016-05-23 bad-data
Not reported 2012-004793-26 AN OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY COMPARING TAS-102 VERSUS TOPOTECAN OR AMRUBICIN IN PATIENTS REQUIRING SECOND-LINE CHEMOTHERAPY FOR SMALL CELL LUNG CANCER THAT IS REFRACTORY OR SENSITIVE TO FI... 2014-06-25 due-trials
Ongoing 2013-004810-16 A dose-finding Phase 1 study of TAS-120 in patients with advanced solid tumors with or without Fibroblast Growth Factor/Receptor (FGF/FGFR)-related abnormalities followed by a Phase 2 study in patien... not-yet-due
Ongoing 2015-002683-16 RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY EVALUATING TAS-102 PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN PATIENTS WITH METASTATIC GASTRIC CANCER REFRACTORY TO STANDARD TREATMENTS not-yet-due
Completed, report not yet due 2016-001806-40 A Randomized, Open-Label, Multi-Center, International Phase 2 Study of TAS-114 in Combination with S-1 in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer 2018-10-25 not-yet-due
Ongoing 2017-004415-39 A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF TAS0728, AN ORAL COVALENT BINDING INHIBITOR OF HER2, IN SUBJECTS WITH ADVANCED SOLID TUMORS WITH... not-yet-due